


# Digital Biomarkers Market Trends 2023: Advancements in Biomarkers Pushing the Industry to Surpass \$14.7 Billion by 2032

Digital biomarkers market report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics.

WILMINGTON, DELAWARE, UNITED STATES, June 26, 2024
/EINPresswire.com/ -- Allied Market Research published a report titled, "Digital Biomarkers Market by Type (Wearable, Mobile Application, Software, and Others), Application (Cardiovascular Disease, Sleep and



Movement Disease, Neurological Disorders, and Others), and End User (Healthcare Companies, Hospitals, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032." According to the report, the global digital biomarkers market was valued at \$2.1 billion in 2022 and is projected to reach \$14.7 billion by 2032, registering a CAGR of 21.3% from 2023 to 2032.



Growth of the global digital biomarkers market size is majorly driven by high presence of market players who manufacture digital biomarkers, and technological advancements for development."

Allied Market Research

Digital biomarkers are physiological, behavioral, or clinical markers that may be measured and studied using digital technology. Digital biomarkers market are further subdivided into active and passive biomarkers. Active digital biomarkers are gathered during prompted actions. They are captured and generated by smartphones, tablets, and other devices when a person interacts with the device in response to an active prompt.

 $000\ 00000000\ 0000000$ 

https://www.alliedmarketresearch.com/purchase-

#### enguiry/132906

By type, the digital biomarkers market size is classified into wearable, mobile application,

software, and others (sensor, card and implantable). The wearable segment is expected to be the fastest growing segment during the forecast period owing to rise in number of product approvals for wearable and rise in adoption of wearable digital biomarker by population.

By application, the digital biomarkers market size is classified into cardiovascular disease, sleep and movement disease, neurological disorders, and others (respiratory diseases, diabetes, psychiatric and musculoskeletal disorders). The cardiovascular disease segment is projected to be the fastest growing segment during the forecast period owing to rise in prevalence of cardiovascular diseases and high in number of product provision of digital biomarkers for cardiovascular disease monitoring and diagnosis.

By clinical practice, the digital biomarkers market share is classified into monitoring, diagnostic and prognostic. The monitoring segment is projected to be the fastest growing segment during the forecast period owing to rise in adoption of digital biomarkers for monitoring purpose and hogh presence of manufacturers who manufactures digital biomarkers for monitoring.

By end user, the digital biomarkers market analysis is classified into healthcare companies, hospitals, and others (payers and patients). The healthcare companies segment is projected to be the fastest growing segment during the forecast period owing to rise in number of clinical trials and research activities using digital biomarkers by healthcare companies.

## 0000 00 000 0000000 :

Koneksahealth, ActiGraph LLC, Verily Life Sciences LLC, Empatica, Brainomix, Clario, Feel Therapeutics, Sonde Health, Inc., Amgen Inc., AliveCor

The 2023 recession has negatively impacted the global digital biomarkers market, resulting in hiring freezes, budget cuts, or reductions in the workforce. These constraints are projected to limit the availability of skilled personnel to deploy and manage the digital healthcare system. However, the global digital biomarkers market is expected to recover from the negative impact of the recession as demand for new treatment options for chronic diseases rises.

Based on application, the cardiovascular diseases segment held the highest market share in 2022, accounting for nearly two-fifths of the global digital biomarkers market revenue, and is estimated to maintain its lead position throughout the forecast period. Due to the rise in the prevalence of cardiovascular diseases and increased awareness among the public regarding digital biomarkers for cardiac diseases. However, the diabetes segment is projected to manifest

a significant CAGR of 22.3% from 2023 to 2032. Due to the rising prevalence of diabetes.

## 

Powered with Complimentary Analyst Hours and Expert Interviews with Each Report

Comprehensive quantitative and qualitative insights at segment and sub-segment level

Covid 19 impact trends and perspective

Granular insights at global/regional/country level

Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment

Blanket coverage on competitive landscape

Winning imperatives

Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

Based on region, North America held the highest market share in 2022, holding nearly half of the global digital biomarkers market revenue, and is likely to dominate the market during the forecast period. The growth is attributed to the high presence of digital biomarker manufacturers in North America and the rising prevalence of chronic disease. However, the Asia-Pacific region is expected to witness the fastest CAGR of 22.3% from 2023 to 2032. Owing to the rising number of geriatric populations, it is more susceptible to chronic diseases, and an increase in awareness among people regarding digital biomarkers.

#### 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction

& Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X

This press release can be viewed online at: https://www.einpresswire.com/article/723086135

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.